| Autor: |
Costa ML; Center for Pulmonary Imaging Research, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center; Department of Biomedical Engineering, University of Cincinnati; Imaging Research Center, Department of Radiology, Cincinnati Children's Hospital Medical Center., Plummer JW; Center for Pulmonary Imaging Research, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center; Department of Biomedical Engineering, University of Cincinnati., Bdaiwi AS; Center for Pulmonary Imaging Research, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center., Albert BJ; Analytical Technology Group, Aurorium., Fugate EM; Imaging Research Center, Department of Radiology, Cincinnati Children's Hospital Medical Center., Niedbalski PJ; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of Kansas Medical Center; Department of Bioengineering, University of Kansas; Hoglund Biomedical Imaging Center, University of Kansas Medical Center., Lindquist DM; Imaging Research Center, Department of Radiology, Cincinnati Children's Hospital Medical Center; Department of Pediatrics, University of Cincinnati., Cleveland ZI; Center for Pulmonary Imaging Research, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center; Department of Biomedical Engineering, University of Cincinnati; Imaging Research Center, Department of Radiology, Cincinnati Children's Hospital Medical Center; Department of Pediatrics, University of Cincinnati; Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center; Zackary.Cleveland@cchmc.org. |
| Abstrakt: |
Hyperpolarized (HP) xenon-129 ( 129 Xe) is an inhaled magnetic resonance imaging (MRI) contrast agent with unique spectral and physical properties that can be exploited to quantify pulmonary physiology, including ventilation, restricted diffusion (alveolar-airspace size), and gas exchange. In humans, it has been used to evaluate disease severity and progression in a variety of pulmonary disorders and is approved for clinical use in the United States and United Kingdom. Beyond its clinical applications, the ability of 129 Xe MRI to noninvasively assess pulmonary pathophysiology and provide spatially resolved information is valuable for preclinical research. Among animal models, mice are the most widely used due to the accessibility of genetically modified disease models. Here, 129 Xe MRI is promising as a minimally invasive, radiation-free, and sensitive technique to longitudinally monitor lung disease progression and therapy response (e.g., in drug discovery). This technique can extend to preclinical applications by incorporating an MRI-triggered, free-breathing apparatus or mechanical ventilator to deliver gas. Here, we describe the steps and provide checklists to ensure robust data collection and analysis, including creating a thermally polarized xenon gas phantom for quality control, optimizing polarization, animal handling (sedation, intubation, ventilation, and care for mice), and protocols for ventilation, restricted diffusion, and gas exchange data. While preclinical 129 Xe MRI can be applied in various animal models (e.g., rats, pigs, sheep), this protocol focuses on mice due to the challenges posed by their small anatomy, which are balanced by their affordability and the availability of many disease models. |
